Experimental Obesity Drug Reduces Sleep Apnea Symptoms

• An experimental obesity drug reduced breathing interruptions and other symptoms of obstructive sleep apnea in two clinical trials.
• The drug, retatrutide, was developed by Eli Lilly and tested in clinical trials.
• Obstructive sleep apnea affects over 50 million Americans, with about 80% of cases undiagnosed.
• The research was published in The New England Journal of Medicine.
• The study found that retatrutide significantly reduced apnea episodes compared to a placebo.